2019 Presentations

Sessions and presentations will be added as permissions are provided.

Presentations are provided in PDF with author's permission. Use the links below to find the session you're looking for. For
presentations that are not provided, contact IMPAACT Operations for contact information.

 

Drop down to presentations:

IMPAACT Plenary

TB Scientific Committee

Treatment Scientific Committee

Complications and Co-Morbidities Scientific Committee

Prevention Scientific Committee

Study Coordinators Meeting

Lab

Other

ICAB

 

IMPAACT Plenary

Wednesday, 12 June 2019

Moderators:
Sharon Nachman, MD and James McIntyre, MD (1st half)
James McIntyre, MD and Steven Douglas, MD (2nd half)

State of the IMPAACT Network

Sharon Nachman, MD

PROMISE Findings: What's New? What Have We Learned?

Mary Glenn Fowler, MD, MPH

Pediatric Medicines: Evolution by Revolution Martina Penazzato, MD

NIAID: State of the Institute and Priorities for HIV/AIDS Research

 

Anthony Fauci, MD

Central Nervous System Outcomes in Perinatal HIV: Neurobehavior and Neurobiology

 

Susan Morgello, MD

Broadly Neutralizing Antibodies to Reduce Vertical HIV Transmission: Safety and PK of VRC01 and VRCO1LS

 

Coleen Cunningham, MD

 

TB Scientific Committee

Tuesday, 11 June 2019

Welcome and Overview of Tuberculosis Scientific Agenda

Anneke Hesseling Amita Gupta

Ultrashort Regimens for TB Prevention in Children and Pregnant Women

Nicole Salazar-Austin Sylvia LaCourse

Optimizing Rifampicin Exposures in Children with Severe and Non-severe TB: the OptiRif Kids trial

 

Anthony Garcia-Prats

Improving Access to Anti-tuberculosis Drugs for Children: Updates from the World Health Organization

 

Martina Penazzato


TB Vaccines: State of the Art

 

Ann Ginsberg


Novel Serum-based Biomarkers for TB Diagnosis in Children

 

Tony Hu

 

Treatment Scientific Committee

Tuesday, 11 June 2019

Welcome and Overviewof Treatment Scientific Agenda

Ted Ruel

Global HIV Treatment Landscape: What’s Next for Women and Children

Martina Penazzato

Current Pipeline of Long-Acting Formulations and Products: Implications for Infants, Children, Adolescents, and Pregnant Women

 

Charles Flexner

Treatment Studies in the Pipeline

Ted Ruel


IMPAACT Treatment Scientific Committee Members Discussion: What’s Next on the Treatment Horizon?

 

Treatment Scientific Committee Members 3

 

Complications and Co-Morbidities Scientific Committee

Wednesday, 12 June 2019

Committee Overview

Allison Agwu

Pregnancy: A Window of Opportunity to Test and Treat Hepatitis C Virus

Catherine Chappell

New-Onset Seizures in Children with HIV

David Bearden

IMPAACT 2002: Combined Cognitive Behavioral Therapy and a Medication Management Algorithm for Treatment of Depression among Youth Living with HIV in the United States

 

Larry Brown


IMPAACT 2016: Evaluating a Group-Based Intervention to Improve Mental Health and ART Adherence Among Youth Living with HIV in Low Resource Settings

 

Geri Donenberg, Dorothy Dow


RSV Studies IMPAACT 2011, 2012, 2013, 2018, 2021: Randomized Phase I Studies of the Infectivity, Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines or Placebo, Delivered as Nose Drops to RSV-Seronegative Children 6 to 24 Months of Age

 

Betsy McFarland, Coleen Cunningham


Concept Sheet 5020: Low Dose Aspirin for Prevention of Preterm Birth in Women Living With HIV-1

 

Adriana Weinberg

 

 

Prevention Scientific Committee

Thursday, 13 June 2019

Welcome: Overview of Prevention Agenda

Lynda Stranix-Chibanda

HIV Drug Resistance at Mother-to-Child Transmission and Emergence during Breastfeeding

Ceejay Boyce

Infant Growth Updates: P1084s and Neurodevelopmental Growth Findings with ARV Exposure

Jim Aizire

The Outcome of Subsequent Pregnancies in PROMISE 1077BF and 1077FF

Gerhard Theron


Future Plans and Remaining Gaps in Knowledge

Mary Glenn Fowler


Study Update, IMPAACT 2009: Pharmacokinetics, Feasibility, Acceptability, and Safety of Oral Pre-Exposure Prophylaxis for Primary HIV Prevention during Pregnancy and Postpartum in Adolescents and Young Women and their Infants


Phionah Kibalama


PrEP in Pregnancy: Ongoing Projects and Gaps

Grace John-Stewart


Study Update, IMPAACT P1112: Phase I Study to Determine Safety and Pharmacokinetic Parameters of Subcutaneous VRC01, a Potent Anti-HIV Neutralizing Monoclonal Antibody, in HIV-1 Exposed Infants

 

Coleen Cunningham


Cost-Effectiveness of Broadly Neutralizing Antibodies for PMTCT in Resource-Limited Settings

 

Andrea Ciaranello


Study Overview: A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of the HIV-1 CH505 Transmitted/Founder gp120 Adjuvanted with GLA-SE in Healthy, HIV-exposed Uninfected Infants

 

Avy Violari

 

Study Coordinators Meeting

Thursday, 13 June 2019

Recent Updates and Guidelines from DAIDS

Anne Coletti

DAIDS Clinical Trials Insurance Requirement, memorandum dated 10 August 2018: Tips for Documentation Needed for CTI as part of Study Activation

Emily Brown

Overview of Relevant Sections of the IMPAACT Network Manual of Procedures

Katie McCarthy

IMPAACT Study Milestones

All

 

Lab

LDMS End User Validation Lab Assistance Program

Colleen Woodworth

Applications of Antiviral Adherence Monitoring with Dried Blood Spots (DBS)

Kristina Brooks

 

Other

P1090 and P1093 Regulatory Inspection Preparadness

Ellen Townley and Teri Greenfield

Updates: The Revised Common Rule, Informed Consent Process Policy, Age & Identity Verification Policy, Delegation of Duties Policy, and Clinical Quality Mangement Plan Policy

DAIDS OPCRO and OCSO staff

Good Documentation Practices

Sheryl Zwerski

 

ICAB

Skills Building Session: Understanding Informed Consent and Assent

Anne Coletti, FHI 360

Education Session: Undetectable = Untransmittable: Understanding Treatment as Prevention (TasP) and PreExposure Prophylaxis (PrEP)

U=U and how one CAB, our UCLA CAB, made a difference

Jonathan Lucas, FHI 360

 

 

Jayda Arrington – Los Angeles, CA USA

HIV Cure

Cure Scientific Committee Update

Dr. Deborah Persaud

HIV Treatment

Treatment Scientific Committee Update

Dr. Ted Ruel

Baylor - Uganda CAB and Community Activities

Nagawa Jaliaah

HIV Prevention

Prevention Scientific Committee Update

Dr. Lynda Stranix-Chibanda

IMPAACT Community and Science HIV Prevention

Dichaba Siane

Tuberculosis

TB Scientific Committee Update

Dr. Amita Gupta

UZCHS_CRTC IMPAACT Community Advisory Board

Maximina Jokonya

HIV Complications and Comorbidities

Complications Scientific Committee Update

Dr. Allison Agwu

Community Activities for IMPAACT 2016

Steven Mphonda

 

Study Overviews

 

 

 

 

 

 

 

 

 

 


 

 

Funded by the National Institute of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and the National Institute of Mental Health of the US National Institutes of Health, US Department of Health and Human Services.